2021
DOI: 10.1002/iju5.12261 View full text |Buy / Rent full text
|
|

Abstract: Introduction Metastatic renal cell carcinoma is treated with various regimens. As their outcomes are improving and follow‐up periods are growing longer, the rate of unusual visceral metastases may increase. Case presentation A 68‐year‐old man diagnosed with lung, pancreatic, and renal metastases 9 years after left partial nephrectomy and a diagnosis of pT1a clear cell renal cell carcinoma started molecular targeted therapy using sunitinib. Nine years after the initiation of targeted therapy, a mass lesion in t… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles